ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Solasia Pharma KK

Business Summary

Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. It expedites patient access to Western oncology and hematology therapies by developing products licensed from Western pharmaceutical and biotechnology companies. The company was founded by Bard Geesaman, John McDonald, and Koji Shinozaki in December 2006 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2018 JPYUSD
Revenue318M2.87M
Gross Profit-48M-0.43M
Operating income-2,419M-21.90M
Income before tax-2,445M-22.13M
Net income-2,422M-21.92M
EBITDA-2,266M-20.51M
Diluted EPS-25.97-0.23
Dividends Per Share00
Total Assets8,672M79.04M
Total liabilities1,584M14.43M
Total equity7,087M64.59M
Operating cash flow-2,323M-21.03M
Currency in JPYCurrency in USD

Historical Data

 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 11.95M 229.46M 501.31M 410.85M 318M
Gross Profit 11.49M 228.52M 500.43M 410.32M -48M
Operating income -702.01M -702.42M -462.47M -1,009.68M -2,419M
Income before tax -701.98M -710.75M -494.63M -1,016.28M -2,445M
Net income -677.03M -643.88M -474.43M -1,007.48M -2,422M
EBITDA -701.54M -701.48M -461.59M -1,009.15M -2,266M
Diluted EPS -26.90 -24.83 -18.46 -12.24 -25.97
Dividends Per Share -- -- -- 0 0
Total Assets 2,204.82M 4,710.89M 4,451.44M 7,566.64M 8,672M
Total liabilities 1,951.25M 3,712.05M 1,017.97M 1,358.08M 1,584M
Total equity 253.55M 998.84M 3,433.46M 6,208.55M 7,087M
Operating cash flow -631.81M -699.62M -464.98M -911.39M -2,323M
 Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018
Revenue 0.11M 1.89M 4.61M 3.66M 2.87M
Gross Profit 0.10M 1.88M 4.60M 3.65M -0.43M
Operating income -6.63M -5.80M -4.25M -9.00M -21.90M
Income before tax -6.63M -5.87M -4.55M -9.06M -22.13M
Net income -6.39M -5.31M -4.36M -8.98M -21.92M
EBITDA -6.62M -5.79M -4.24M -8.99M -20.51M
Diluted EPS -0.25 -0.20 -0.16 -0.10 -0.23
Dividends Per Share -- -- -- 0 0
Total Assets 18.38M 39.16M 38.16M 67.16M 79.04M
Total liabilities 16.27M 30.85M 8.72M 12.05M 14.43M
Total equity 2.11M 8.30M 29.43M 55.11M 64.59M
Operating cash flow -5.96M -5.77M -4.27M -8.12M -21.03M

Valuation Measures

Dec 2018
PER--
ROA-29.83%
ROE-36.43%
Operating margin-760.69%
Profit margin-761.63%

Key executives

  • President & Representative Director: Yoshihiro Arai
  • CFO, Director & General Manager-Administration: Toshio Miyashita
  • Manager-Business Development: Koji Shinozaki
  • Manager-Accounting: Yasumitsu Shimada

Shareholders

  • ITOCHU Corp. (19.5%)
  • Maruho Co., Ltd. (9.6%)
  • Meiji Holdings Co., Ltd. (3.2%)
  • Lee's Pharmaceutical Holdings Ltd. (1.9%)
  • Mitsui Sumitomo Insurance Venture Capital Co. Ltd. (1.0%)
  • Kyoto KK (0.8%)
  • North Asia University (0.4%)
  • ARAI YOSHIHIRO (0.4%)
  • MIYASHITA TOSHIO /SOLASIA/ (0.3%)
  • Solasia Pharma Employee Incentive Plan (0.2%)

Contact Details

  • Website:http://www.solasia.co.jp
  • Address: Sumitomo Fudosan Shiba-Koen Tower 4F, 2-11-1 Shiba-koen, Tokyo, 105-0011, Japan
  • Phone: +81.3.5843.8045

Related Companies

  • Solasia Pharma Employee Incentive Plan

Competitors

    Last Updated on 28 Jan, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world
    .

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends January 31st

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media